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A mass of epidemiological evidence suggests that Kaposi’s
sarcoma (KS) is caused by a sexually transmitted infectious agent
and is made a thousandfold more frequent by immunodeficiency
(Kinlen, 1996; Moore and Chang, 1998). The newly described
human herpesvirus 8 (HHV-8) has been detected in nearly all
biopsy specimens from patients with all forms of KS (Moore and
Chang, 1998).
The lack of an excess of AIDS-associated KS in southern
Europe, despite the strong geographical predilection described for
classic KS, has long been noticed (Casabona et al, 1991; Ebrahim
et al, 1997; Franceschi et al, 1997) and remains unexplained. In
fact, the prevalence of KS among AIDS patients in Europe accu-
rately reflects the proportion of homosexual and bisexual men
(highest in Denmark, the Netherlands and the United Kingdom)
and of people from Africa (highest in Belgium, France and in the
United Kingdom) (Dal Maso et al, 1995; Parkin et al, 1997). Even
among patients with heterosexually acquired AIDS, however,
southern Europe does not show especially high prevalences of KS
as an AIDS-defining condition. Italy, for instance, is with Iceland
(Hjalgrim et al, 1998) the highest risk country for classic KS
(Parkin et al, 1997), but showed in 1981–94 a prevalence of KS as
an AIDS-defining condition in Italian-born male heterosexuals of
only 7% (IARC, 1996). This proportion is comparable with those
seen in north European countries, where classic KS is very rare,
e.g. 9% in France, 7% in Germany and 5% in the United Kingdom
(IARC, 1996). It has, thus, been suggested that the geographical
variations in classic KS may not be due to differences in preva-
lence of the putative causal virus, but may derive instead from
variations in the prevalence of some form of mild immuno-
deficiency (Ebrahim et al, 1997).
Non-Hodgkin’s lymphoma (NHL) incidence, as KS incidence,
is greatly increased in immunodeficiency of different origins
(Kinlen, 1996). An excess of skin cancer after NHL and an excess
of NHL after skin cancer have been reported (Adami et al, 1995;
Levi et al, 1996) and attributed to mild immunodepression induced
by sunlight exposure (Cartwright et al, 1994). However, data from
the United States showed that sunlight did not bear the same clear
relationship to all NHL (Hartge et al, 1996; Newton, 1997) or to
primary cutaneous NHL (Newton, 1997) that was evident in the
geographical variation of melanoma of the skin or non-melanoma-
tous skin cancer. Except for a very rare variety (body cavity-based
lymphoma), NHL is not associated with HHV-8 (Cesarman et al,
1995). It is, thus, of interest to examine the most recent (1988–92)
incidence rates of non-AIDS KS and NHL in different European
countries (Parkin et al, 1997) for evidence of a correlation between
these malignancies.
MATERIALS AND METHODS
Age-standardized (world population) incidence rates per 100 000
population in 1988–92 have been derived either for whole nations
(e.g. Nordic countries) or for a combination of all available cancer
registries (ranging from two for Germany to 13 for Italy) (Parkin et
al, 1997). Israel is part of the World Health Organization European
Region and was also examined. A few countries (i.e. Austria,
Croatia, Ireland, Latvia and Slovenia) for which KS incidence
rates were not available (Parkin et al, 1997) have not been consid-
ered. Restriction to cancer diagnoses in individuals age 60 years or
more should have largely eliminated the confounding influence of
AIDS because only about 3% of AIDS cases occur above this age
in the countries examined (Dal Maso et al, 1995).
RESULTS
Standardized incidence rates per 100 000 for KS and NHL in men
and women age 60 years or more are given in Table 1 for 19
European countries. KS incidence ranged from 0.1 (Germany and
Scotland) to 15.5 (Israel) in men and 0.02 (Slovakia) to 5.5 (Israel)
in women. The range for NHL was also substantial: from 13.3
(Belarus) to 59.0 (Switzerland) in men and from 7.0 (Belarus) to
48.0 (Israel) in women.
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ItalyPositive correlations emerged between KS and NHL in men
(Spearman non-parametric correlation coefficient, r = 0.59, P =
0.01) (Figure 1A) and women (r = 0.46, P = 0.05). The exclusion
of Iceland and Israel, which could be considered outliers, affected
correlation coefficients very little (r = 0.62 in men and 0.44 in
women).
However, within the highest-risk countries where regions or
groups could be assessed separately, internal correlations did not
confirm the pattern suggested above. Among 13 Italian cancer
registries, KS and NHL incidence rates were not correlated:
Spearman r = 0.04, P = 0.90, in men (Figure 1B) and r = 0.08,
P = 0.80, in women. In Israel, where four major groups can be
distinguished by Jewish ancestry and place of birth, KS incidence
was highest among Jews born in Africa or Asia (25.5 per 100 000
men and 7.6 per 100 000 women). Conversely, NHL incidence
was highest among Jews born in Europe or America for men
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Table 1 Standardized (world) incidence rates per 100 000 population of Kaposi’s sarcoma and non-Hodgkin’s lymphoma in men and women age 60 years or
more in 19 European countries, 1988–92 (Parkin et al, 1997)
European countries Kaposi’s sarcoma Non-Hodgkin’s lymphoma
Men Women Men Women
No. Rate No. Rate No. Rate No. Rate
Belarus 14 0.59 9 0.18 358 13.28 374 6.99
Czech Republic 18 0.48 11 0.18 1183 31.93 1311 21.76
Denmark 4 0.16 2 0.05 1092 44.89 1107 32.39
England and Walesa 27 0.21 11 0.05 6341 44.76 6348 30.18
Estonia 1 0.25 1 0.13 97 21.02 95 10.53
Finland 49 2.19 33 0.60 1100 50.52 1508 39.67
Francea 29 1.44 8 0.26 999 45.97 1099 33.37
Germanya 3 0.12 1 0.01 739 28.54 948 18.67
Iceland 13 13.09 10 5.38 34 36.54 26 22.40
Israel 245 15.52 113 5.47 824 57.69 847 47.96
Italya 150 4.12 71 1.09 1927 54.54 1947 37.06
Netherlands 31 0.70 9 0.10 2387 51.47 2382 33.98
Norway 43 1.70 29 0.89 981 46.47 958 32.67
Polanda 4 0.21 2 0.07 429 22.59 358 11.99
Scotland 3 0.12 4 0.17 970 43.62 1299 38.25
Spaina 27 0.90 10 0.19 898 29.86 913 22.83
Slovakia 6 0.38 1 0.02 390 23.61 376 15.90
Sweden 99 1.70 42 0.52 2600 54.79 2311 36.10
Switzerlanda 14 0.91 3 0.11 913 58.99 916 38.41
aRates refer to some areas only.
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Figure 1 Correlation between standardized (world) incidence rates per 100 000 population of Kaposi’s sarcoma (KS) and non-Hodgkin’s lymphoma (NHL) in
men age 60 years or more in 19 European countries and in 13 Italian cancer registries, 1988–92 (Parkin et al, 1997). r represents the Spearman correlation
coefficient. aBLR, Belarus; CZH, Czech Republic; DEN, Denmark; ENG, England and Wales; EST, Estonia; FIN, Finland; FRA, France; GER, Germany; ICE,
Iceland; ISR, Isreal; ITA, Italy; NET, Netherlands; NOR, Norway; POL, Poland; SCO, Scotland; SPA, Spain; SVK, Slovakia; SWE, Sweden; and SWI,
Switzerland. bFE, Ferrara; FI, Florence; GE, Genoa; LT, Latina; MC, Macerata; MO, Modena; PR, Parma; RG, Ragusa; RO, Romagna; TO, Torino; TS, Trieste;
VA, Varese; and VE, Venetian region(66.0 per 100 000) and among those born in Israel for women
(54.5 per 100 000).
DISCUSSION
Population-based incidence data have a few important limitations
(e.g. lack of distinction between different NHL histological types
and sites, and quality problems, particularly among the elderly and
in large Eastern European registries; Parkin et al, 1997). These
may contribute to the fact that the distribution of classic KS and
NHL in European countries provides only partial and inconsistent
support to a link between KS and NHL outside AIDS. Israel and
Italy show a high incidence of both KS and NHL but Iceland,
whose KS excess clearly antedates AIDS (Hjalgrim et al, 1998),
has only intermediate NHL rates. The lack of a clear NHL excess
in individuals with a previous diagnosis of classic KS (Biggar et al,
1994; Franceschi et al, 1996; Hjalgrim et al, 1997) also weighs
against the ‘mild immunodeficiency’ hypothesis, although larger
and better studies should clarify this issue further.
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